Lipocine INC

Lipocine Inc. announced its second quarter 2026 financial results and provided a corporate update, highlighting a missed primary endpoint in its LPCN 1154 Phase 3 trial for postpartum depression.

Lipocine Inc. announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026, to enhance its strategic development and partnership efforts.

Lipocine Inc. conducted a virtual key opinion leader event to discuss the clinical profile of LPCN 1154 for treating postpartum depression.

Lipocine Inc. announced that shareholders approved amendments to its 2014 Stock and Incentive Plan, increasing award limits and authorized shares, and re-elected directors at the annual meeting.

Lipocine Inc. announced a virtual Key Opinion Leader event on June 12, 2026, to discuss unmet needs in postpartum depression and the clinical profile of its investigational drug LPCN 1154.

Lipocine Inc. presented Phase 3 clinical trial data for LPCN 1154, an oral brexanolone treatment for postpartum depression, at the ASCP Annual Meeting.

Lipocine Inc. (LPCN) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing development efforts, licensing agreements, and financial performance, including a significant setback in its LPCN 1154 Phase 3 trial for postpartum depression.

Lipocine Inc. reported Q1 2026 results, highlighting a significant setback in its LPCN 1154 Phase 3 trial for postpartum depression, while continuing to advance other pipeline candidates and manage existing licensing agreements.

Lipocine Inc. reported a significant increase in net loss for Q3 and the nine months ended September 30, 2025, driven by higher R&D expenses for its CNS pipeline, despite new licensing agreements for TLANDO.

Lipocine Inc. reported a reduced net loss for Q2 2025 compared to the prior year, driven by increased license and royalty revenues, while advancing multiple clinical programs and securing new international TLANDO licenses.

Lipocine Inc. announces its financial results for the first quarter of 2025, highlighting royalty revenue of $94,000 and ongoing development of its pipeline candidates.

Lipocine Inc. announced its financial results for the third quarter of 2024, highlighting progress in its clinical programs and licensing agreements.

Lipocine Inc. announces its financial results for the year ended December 31, 2024, and provides an update on its clinical development programs and commercialization efforts.

Lipocine Inc.'s 2023 10-K filing details a strategic shift towards CNS disorders, progress in clinical trials, and new licensing agreements, while also highlighting financial results and future plans.

Michael Grissinger, a Director of Lipocine Inc., received 2,000 shares of common stock on August 3, 2026.

Lipocine Inc. CEO Mahesh V. Patel acquired stock options for 52,781 shares at an exercise price of $2.49, with vesting scheduled over three years.

Lipocine Inc. director John W. Higuchi acquired stock options with a potential exercise price of $2.19.

Lipocine Inc. director Jill M. Jene acquired stock options for 1,764 shares of common stock.

Lipocine Inc. director Richard Dana Ono acquired 1,764 shares of common stock through the exercise of a right to buy, with a conversion price of $2.19.

Lipocine Inc. director John W. Higuchi acquired 40,000 shares of common stock.

Lipocine Inc. has filed its proxy statement for the 2026 Annual Meeting of Stockholders to be held on June 3, 2026.

Lipocine Inc. is set to hold its 2025 Annual Meeting of Stockholders on June 4, 2025, featuring proposals including the election of directors, ratification of the accounting firm, an advisory vote on executive compensation, and a significant decrease in authorized common stock shares.

Lipocine Inc. amends its 2014 Stock and Incentive Plan to increase the authorized number of shares and prohibit option repricing without stockholder approval, seeking ratification at the upcoming annual meeting.

Lipocine Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 5, 2024, to address key proposals including the election of directors, ratification of the accounting firm, executive compensation, and an amendment to the stock and incentive plan.

Squadron Master Fund LP, along with its affiliates, has reported beneficial ownership of 810,000 shares, representing 9.8% of Lipocine Inc.'s common stock.

Squadron Master Fund LP and its affiliates report a 6.2% stake in Lipocine Inc. common stock as of March 31, 2026.

Squadron Master Fund LP and its affiliates reported a 9.5% beneficial ownership stake in Lipocine Inc. common stock, held for ordinary business purposes.

Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have reported beneficial ownership of Lipocine Inc. common stock, with Squadron Capital Management and its partners holding 9.0%.